Brean Murray Carret & Co Revises EPS Estimates Of Gilead

Loading...
Loading...
According to Brean, Gilead Sciences
GILD
, EPS estimates have changed. Brean reported a change in EPS estimates from $3.91 to $3.65 for FY11 and from $4.40 to $4.22 for FY12. Rating is set to Buy with a PT of $52. Gilead closed yesterday at $35.34.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsBiotechnologyBrean Murray Carret & CoHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...